JE
Jenburkt Pharmaceuticals Ltd (JENBURPH)
₹893.20
Mkt cap
₹408 Cr
P/E ratio
11.40
P/B
1.93
Div yield
2.24%
ROE
20.20%
ROCE
27.00%
EPS (TTM)
₹78.35
Book value
₹464
52W range
34–1,074
Sector
Healthcare
Price history
Previous close
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products [1]
NSE JENBURPHBSE 524731
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−16.83% from high₹893
₹34+2,496.51% from low₹1,074
Current
₹893.20
Prev close
₹900.30
Day
−0.79%
Price performance
1D
−0.92%
1W
−7.37%
1M
+2.37%
3M
−14.68%
6M
—
1Y
—
YTD
−14.53%
Financials
Revenue, profit & margin
P/E ratio
11.4×
JENBURPH is 65% below the sector median of 32.8×
JENBURPH11.4×
Sector median32.8×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 36 | 39 | 33 | 41 | 37 | 41 | 36 | 46 | 43 | 45 | 36 | 48 | |
| YoY Sales growth | +7% | +3% | +10% | +12% | +8% | +3% | +6% | +9% | +11% | +17% | +9% | -0% | +6% | |
| Expenses | 29 | 28 | 29 | 23 | 30 | 28 | 30 | 27 | 32 | 36 | 30 | 29 | 35 | |
| Operating Profit | 9 | 7 | 10 | 9 | 11 | 9 | 11 | 9 | 13 | 7 | 14 | 6 | 13 | |
| OPM % | 24% | 20% | 25% | 29% | 28% | 24% | 26% | 25% | 29% | 17% | 32% | 17% | 27% | |
| Other Income | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Profit before tax | 10 | 8 | 10 | 10 | 13 | 10 | 12 | 10 | 14 | 8 | 14 | 7 | 14 | |
| Tax % | 23% | 31% | 24% | 26% | 23% | 32% | 28% | 23% | 29% | 29% | 21% | 13% | 29% | |
| Net Profit | 7 | 5 | 8 | 7 | 10 | 7 | 9 | 8 | 10 | 6 | 11 | 6 | 10 | |
| EPS in Rs | 16.59 | 12.24 | 17.86 | 16.81 | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 | 23.13 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202646.62%Promoter
Promoters46.62%
DIIs0.03%0.09
Public53.34%0.07
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,871.50 | 36.49 | 4,49,036 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,049.00 | 85.83 | 2,93,316 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,610.70 | 80.78 | 1,75,376 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,322.50 | 93.66 | 1,25,488 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,202.00 | 26.46 | 1,19,900 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,398.20 | 41.71 | 1,16,788 | 0.57% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,417.00 | 36.86 | 1,14,478 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Jenburkt Pharma | ₹924.45 | 11.40 | 408 | 2.24% | 10 | +0.49% | 48 | +6.06% | 26.95% |
| Median: 160 Co. | ₹439.32 | 32.75 | 2,001 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings1
Announcements5
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 4 NovAnnouncement under Regulation 30 (LODR)-Newspaper Publication 4 Nov - Newspaper Publication for standalone Unaudited financial results for the quarter and half year ended on 30th September, 2026.Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 03Rd November, 2026. 3 Nov - Board approved Q2 and H1 FY2026 standalone results on 3 November 2026.Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2026 3 Nov - Jenburkt approved Q2 and H1 FY2026 standalone results; PAT rose to Rs 1,609.50 lakh.Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2026. 29 Oct - Board meeting on 3 November 2026 to approve standalone unaudited Q2 and half-year FY2026 results.






